Heineken warns British pubs and bars about the use of slimming agents

Heineken acknowledges the impact of GLP-1 weight loss medications on beer consumption, advising pubs to promote smaller drinks and low-alcohol options. The company has observed changes in drinking habits among users of these medications, who tend to prefer lighter alcoholic beverages. Heineken maintains regular communication with the UK hospitality sector to share market insights and trends. Despite the challenges posed by these medications, the brewer believes it can adapt its product offerings to meet evolving consumer preferences.